Edgewise Therapeutics (EWTX)

Edgewise Therapeutics Stock Analysis & Ratings

EWTX Stock Chart & Stats

Day’s Range$7.61 - $8.005
52-Week Range$6.93 - $29.98
Previous Close$7.47
Average Volume (3M)320.94K
Market Cap$388.18M
P/E Ratio-9.0
Next EarningsAug 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-0.87



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $6.93 and its highest was $29.98 in the past 12 months.
    What is Edgewise Therapeutics’s market cap?
    Edgewise Therapeutics’s market cap is $388.18M.
      What is Edgewise Therapeutics’s price target?
      The average price target for Edgewise Therapeutics is $8.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $8.00 ,the lowest forecast is $8.00. The average price target represents 2.17% Increase from the current price of $7.83.
        What do analysts say about Edgewise Therapeutics?
        Edgewise Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Edgewise Therapeutics’s upcoming earnings report date?
          Edgewise Therapeutics’s upcoming earnings report date is Aug 08, 2022 which is in 84 days.
            How were Edgewise Therapeutics’s earnings last quarter?
            Edgewise Therapeutics released its earnings results on May 11, 2022. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.278 by -$0.022.
              Is Edgewise Therapeutics overvalued?
              According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
                Does Edgewise Therapeutics pay dividends?
                Edgewise Therapeutics does not currently pay dividends.
                What is Edgewise Therapeutics’s EPS estimate?
                Edgewise Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Edgewise Therapeutics have?
                Edgewise Therapeutics has 49,580,000 shares outstanding.
                  What happened to Edgewise Therapeutics’s price movement after its last earnings report?
                  Edgewise Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.278. Following the earnings report the stock price went down -3.81%.
                    Which hedge fund is a major shareholder of Edgewise Therapeutics?
                    Among the largest hedge funds holding Edgewise Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Edgewise Therapeutics’s shares valued at 15M.


                      Edgewise Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(2.17% Upside)
                      Moderate Buy
                      The Edgewise Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Edgewise Therapeutics

                      Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis